Arthur D. Little Announces Promotion of Seven New Partners as the Consultancy Continues Its Global Expansion
Arthur D. Little (ADL) today announced the promotion of seven of its consultants to the rank of Partner, in recognition of the expertise and depth of experience that each one brings to the company. These appointments represent a major milestone for ADL, with the company now boasting over 100 Partners within its global team. Over the past five years, ADL has doubled in size by pursuing a dynamic growth path, and one of the key tenets of its ongoing success is the development and promotion of its internal talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005042/en/
Arthur D. Little has reached the 100+ partners milestones, with the promotion of seven partners. (Photo: Business Wire)
The latest appointments to Partner are as follows:
- Matteo Ainardi, Partner, Automotive and Manufacturing (AMG) and Strategy & Organization (S&O) Practices. Matteo joined ADL in 2016 and currently leads the company’s global Aerospace & Defense Center of Competence. His main focus is on supporting clients in the A&D ecosystem, focusing on strategy definition, organizational redesign and innovation management.
- Lokesh Dadhich, Partner, Telecommunication, Information, Media & Electronics (TIME) and Operations Management (OM) Practices. Lokesh joined ADL in 2007 and is based out of the company’s Dubai office. His main areas of expertise are in Digital Strategy, Customer Experience, and Operations Excellence topics. He advises clients in the TIME industry and beyond on strategy, operations, and transformation challenges.
- Naoya Furuta, Partner, Operations Management (OM) Practice. Naoya joined ADL’s Tokyo office as a Manager in 2016, and has experience across multiple industries, with a particular focus on manufacturing and construction. His main areas of expertise include company-wide strategic planning, corporate management, corporate reform, M&A advisory and PMI.
- Trung Ghi, Partner, Energy & Utilities (ENUT) Practice. With more than 20 years of experience in the oil and gas industry, Trung currently leads ADL’s ENUT Practice in South-East Asia, and has been responsible for opening a number of key accounts. He has been a driving force in positioning ADL as a go-to management consulting firm within SEA’s energy sector.
- Max Scherr, Partner, Strategy & Organization (S&O) Practice. With over 20 years of experience in strategy consulting as a senior executive, Max joined ADL in 2018 and leads the company’s S&O Practice in its Vienna office. His specializations include Digital Transformation, Information Security, Growth and Corporate Strategy.
- Ben Thuriaux-Alemán, Partner, Energy & Utilities (ENUT) and Technology & Innovation Management (TIM) Practices. With over 20 years of consulting experience, Ben has played a major role in developing ADL’s TIM Practice, and currently runs the company’s Global Innovation Excellence Benchmarking diagnostic. His particular focus is on aligning innovation with corporate strategy, and working on national innovation initiatives.
- Marten Zieris, Partner, Strategy & Organization (S&O) Practice. Marten joined ADL in 2010 and is based out of its Frankfurt office. He is responsible for the company’s competence center “Organization & Transformation” in Central Europe and supports international clients in large-scale transformations end to end, “from concept development to implementation”. Marten also has a specialist focus on consumer products businesses.
Ignacio García Alves, Chairman and CEO of Arthur D. Little, comments: “I would like to congratulate these new Partners – and welcome them as the first members of ADL’s ‘Generation 100’! Each promotion is richly deserved and a recognition of the vital contribution that each Partner makes to our company. At ADL, we strive to employ and develop consultants who are both entrepreneurs and team players, and aspire to deliver consultancy at the highest level – as such, having over 100 Partners within ADL truly is a momentous achievement.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005042/en/
Contact information
Sue Glanville/Cate Bonthuys
Catalyst Comms
+44 7715 817589
info@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom